Detalhe da pesquisa
1.
A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib.
Cancer
; 120(8): 1145-54, 2014 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-24501009
2.
Safety and efficacy of dacomitinib in korean patients with KRAS wild-type advanced non-small-cell lung cancer refractory to chemotherapy and erlotinib or gefitinib: a phase I/II trial.
J Thorac Oncol
; 9(10): 1523-31, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-25521398
3.
Health-related quality of life in patients with advanced nonsquamous non-small-cell lung cancer receiving bevacizumab or bevacizumab-plus-pemetrexed maintenance therapy in AVAPERL (MO22089).
J Thorac Oncol
; 8(11): 1409-16, 2013 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-24077452
4.
Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.
J Clin Oncol
; 30(27): 3337-44, 2012 Sep 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-22753918